

41. Douglas Rollins, Mt. Juliet, Tennessee, Court of Federal Claims No: 25–0817V
42. Cynthia Feuling, Oconomowoc, Wisconsin, Court of Federal Claims No: 25–0820V
43. Michelle Purdy, Nebraska City, Nebraska, Court of Federal Claims No: 25–0821V
44. Bianca Chery, Brockton, Massachusetts, Court of Federal Claims No: 25–0822V
45. Blair Leishman, American Fork, Utah, Court of Federal Claims No: 25–0823V
46. Nethaniel Amanfo, Marietta, Georgia, Court of Federal Claims No: 25–0824V
47. Susan Bohall, Denham Springs, Louisiana, Court of Federal Claims No: 25–0825V
48. Prudensiana Lewis, Katy, Texas, Court of Federal Claims No: 25–0829V
49. Edessa Katie Daniel, Los Angeles, California, Court of Federal Claims No: 25–0833V
50. Shalandra Quick, Chicago, Illinois, Court of Federal Claims No: 25–0834V
51. Paige Crum, Springfield, Illinois, Court of Federal Claims No: 25–0835V
52. Michael Bruno, Long Island, New York, Court of Federal Claims No: 25–0836V
53. Susan Vasileff, Sturgeon, Missouri, Court of Federal Claims No: 25–0837V
54. Elizabeth Stelly, City of Industry, California, Court of Federal Claims No: 25–0838V
55. Thomas Church, III, Edgerton, Minnesota, Court of Federal Claims No: 25–0839V
56. Curtis Waits, Redgranite, Wisconsin, Court of Federal Claims No: 25–0840V
57. Marcus Bunton, Bowling Green, Kentucky, Court of Federal Claims No: 25–0841V
58. Jose Antonio Inoa Almonte, Stormville, New York, Court of Federal Claims No: 25–0843V
59. Larry Miller, American Canyon, California, Court of Federal Claims No: 25–0844V
60. Betsy File, Salisbury, North Carolina, Court of Federal Claims No: 25–0845V
61. Nadya Lazarev, New York, New York, Court of Federal Claims No: 25–0846V
62. Janette Glaser, Huntington Beach, California, Court of Federal Claims No: 25–0847V
63. Melvin L. Terry, Allouez, Wisconsin, Court of Federal Claims No: 25–0848V
64. Kyle Muro, Berkeley, California, Court of Federal Claims No: 25–0849V
65. Marci Neustadt, Westlake Village, California, Court of Federal Claims No: 25–0854V
66. Nicole Wood, Woodridge, Illinois, Court of Federal Claims No: 25–0856V
67. Mecquon J. Jones, Fox Lake, Wisconsin, Court of Federal Claims No: 25–0857V
68. Jose Burgos, Dresher, Pennsylvania, Court of Federal Claims No: 25–0860V
69. LaAsia Benford, Acworth, Georgia, Court of Federal Claims No: 25–0861V
70. David Bye, San Francisco, California, Court of Federal Claims No: 25–0862V
71. Gary Sunderland, Dresher, Pennsylvania, Court of Federal Claims No: 25–0863V
72. John A. Rafter, Jr., Portland, Oregon, Court of Federal Claims No: 25–0864V
73. Julie Wakely, Colts Neck, New Jersey, Court of Federal Claims No: 25–0866V
74. Haley Whisenhunt, Chagrin Falls, Ohio, Court of Federal Claims No: 25–0868V
75. Tanya Nelson, Dresher, Pennsylvania, Court of Federal Claims No: 25–0869V
76. Lisa Alber, Dresher, Pennsylvania, Court of Federal Claims No: 25–0870V
77. Kenneth Paciocco, Schertz, Texas, Court of Federal Claims No: 25–0873V
78. Mitchell L. Katzman, Raleigh, North Carolina, Court of Federal Claims No: 25–0879V
79. Cheri Ronan, Dresher, Pennsylvania, Court of Federal Claims No: 25–0880V
80. Ednaly Meza, New York, New York, Court of Federal Claims No: 25–0881V
81. Cynthia Burke, Ferndale, Michigan, Court of Federal Claims No: 25–0884V
82. Nicole Strong, Cedar Springs, Michigan, Court of Federal Claims No: 25–0885V
83. Dawnetta Hayes, Cincinnati, Ohio, Court of Federal Claims No: 25–0886V
84. Michael Boddie, Danville, Pennsylvania, Court of Federal Claims No: 25–0887V
85. Justin Chambers, Bee Cave, Texas, Court of Federal Claims No: 25–0888V
86. Laura Day, Macon, Georgia, Court of Federal Claims No: 25–0889V
87. Taneshia Kendrick on behalf of C.C., Washington, District of Columbia, Court of Federal Claims No: 25–0892V
88. Meaghan Bartlett, Woodridge, Illinois, Court of Federal Claims No: 25–0893V
89. Nicholas Hobbs, Charleston, South Carolina, Court of Federal Claims No: 25–0894V
90. Beth Casteel on behalf of B.C., Denver, Colorado, Court of Federal Claims No: 25–0896V
91. Shari Wilson, Lowell, Massachusetts, Court of Federal Claims No: 25–0897V
92. Shari Smith-Jackson, Dresher, Pennsylvania, Court of Federal Claims No: 25–0898V
93. Maryalice Omokeye Moses, Beverly Hills, California, Court of Federal Claims No: 25–0899V
94. Kathleen Tennaro, Woodridge, Illinois, Court of Federal Claims No: 25–0901V
95. Aubrey L. Hazlett, Raleigh, North Carolina, Court of Federal Claims No: 25–0903V
96. Julie Eusebio, Brookfield, Wisconsin, Court of Federal Claims No: 25–0904V
97. Sara Faux, Dresher, Pennsylvania, Court of Federal Claims No: 25–0905V
98. Allen Barber, Woodridge, Illinois, Court of Federal Claims No: 25–0906V
99. Greer Gisy, Richmond, Virginia, Court of Federal Claims No: 25–0907V
100. Thien Danh, Woodridge, Illinois, Court of Federal Claims No: 25–0908V
101. Russell Senn, White Bear Lake, Minnesota, Court of Federal Claims No: 25–0909V
102. Shara Harbin, Fayetteville, Georgia, Court of Federal Claims No: 25–0911V
103. Rina Mais, Glen Rock, New Jersey, Court of Federal Claims No: 25–0914V
104. Christy Bitterling on behalf of J.B., Los Angeles, California, Court of Federal Claims No: 25–0923V
105. Joshua Carson, Overland Park, Kansas, Court of Federal Claims No: 25–0924V
106. Jerine Coley, Dresher, Pennsylvania, Court of Federal Claims No: 25–0925V
107. Becky Dorris, Dresher, Pennsylvania, Court of Federal Claims No: 25–0927V

Court of Federal Claims No: 25–0927V
 [FR Doc. 2025–11046 Filed 6–13–25; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research for the benefit of the public health.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the licensing contact Michael Shmilovich, Esq.; 301–435–5019; shmilovm@nih.gov, at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, 31 Center Drive, Room 4A25, MSC2479, Bethesda, MD 20892–2479. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404. Technology description follows.

Reversibly Photo-Switchable Fluorescent Proteins for Long-Term Imaging of Live Specimen

Available for research uses, collaboration, and further development are non-cytotoxic reversibly photo-switchable fluorescent mutant proteins that may be locked in a state of high brightness, which may be useful for long-term biomedical applications at routine laser power intensity. Additionally, these proteins offer quick self-recovery of peak fluorescence, which may be useful for imaging of rapid cellular processes.

Inventors

- Vitaly Boyko, Ph.D. (NIBIB)
- George Patterson, Ph.D. (NIBIB)
- Md Abdul Kader Sagar, Ph.D. (NIBIB)

Potential Applications

- Long-term imaging of live specimen, including light-sensitive specimen
- Probe for high-throughput screening applications
- Fluorescent marker in biomedical screening protocols

- Diagnostic tool for cytotoxicity or component of diagnostic kit that utilizes fluorescent proteins.

Licensable Materials

- The nucleotide sequences of fluorescent protein
- Fusion construct to LC3A autophagy marker protein or mitochondria targeted peptide.

Dated: June 10, 2025.

Michael A. Shmilovich,

Acting Director, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2025–10854 Filed 6–13–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by contacting Chris Kornak at 240–627–3705 or at chris.kornak@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:

Technology description follows:

A Novel Strategy To Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

Description of Technology

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent

individuals could prevent a significant amount of human disease.

The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:

- The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.

- The artificial immunogens retained structured transmission blocking epitopes.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

This technology could be used alone or in combination with existing malaria vaccines.

Competitive Advantages:

- The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.

- Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.

Developmental Stage:

- Pre-clinical

Inventors: Dr. Patrick Duffy (NIAID) and Dr. Jonathan Renn (NIAID).

Intellectual Property: HHS Reference No. E–086–2023; Provisional Patent Application No.: 63/617,717, filed on January 4, 2024, and PCT Patent Application No. PCT/US2025/010325, filed on January 3, 2025.

Licensing Contact: To license this technology, please contact Chris Kornak 240–627–3705 or chris.kornak@nih.gov, and reference E–086–2023.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240–627–3705 or chris.kornak@nih.gov, and reference E–086–2023.

Dated: June 9, 2025.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2025–10920 Filed 6–13–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Projects: Cancer Biology.

Date: July 15–16, 2025.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Leila Bahadori Toulabi, Ph.D., Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W334, Rockville, MD 20850, (240) 276–6611, leila.toulabi@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowship: Biophysical, Physiological, Pharmacological and Bioengineering Neuroscience, and Vision.

Date: July 15–16, 2025.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 11601 Landsdown Street, Room 09C63, Bethesda, MD 20892, (301) 594–9460, Soyoun.cho@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel;